Medtronic Inc Receives FDA Approval for Its AFCCC System

Shares of Medtronic, Inc. (MDT) are higher on the session by 2.32%, trading at $37.02. The company today announced that the U.S. Food and Drug Administration [FDA] has approved its Arctic Front® Cardiac CryoAblation Catheter system, the first and only Cryoballoon in the United States indicated for the treatment of drug refractory paroxysmal atrial fibrillation (PAF).

Be the first to comment

Leave a Reply

Your email address will not be published.


*